Showing 451-460 of 7755 results for "".
Teledermatology Update
https://practicaldermatology.com/topics/practice-management/teledermatology-update/20146/Many dermatologists and dermatologic surgeons adopted teledermatology or began to use it more frequently throughout the COVID pandemic. Many consultations and post-operative follow-up appointments were handled through telemedicine platforms. Anthony Rossi, MD talks about the benefits of this technolClinical Conversations: How JAK Inhibitors are Changing the AD Treatment Landscape
https://practicaldermatology.com/series/jak-inhibitors-in-practice/clinical-conversations-how-jak-inhibitors-are-changing-the-ad-treatment-landscape/20092/With the approval of JAK inhibitors to treat eczema, the treatment landscape is changing. Matt Zirwas, MD and Adelaide Hebert, MD talk about the role for JAK inhibitors and key considerations for discussing options with patients.Hormonal Acne Treatment Options
https://practicaldermatology.com/conferences/maui-derm-2022/hormonal-acne-treatment-options/20053/All acne is hormonal acne, says Julie C. Harper, MD. She discusses her approach to treating acne in preadolescents, adolescents, and male and female patients. From the role of oral contraceptives for women to the new topical clascoterone option, she says there are a number of safe and effective treaDermWire TV: Adbry Approved; Syringoma Option; Confusion over Vaccines and Injectables
https://practicaldermatology.com/series/dermwire-tv/dermwire-tv-adbry-approved-syringoma-option-confusion-over-vaccines-and-injectables/20041/Adbry (tralokinumab) from Leo Pharma is the newest biologic approved for moderate to severe atopic dermatitis in adults and is the first IL-13 blocker approved in the US. Pulse Bioscience’s nano-pulse stimulation (NPS) technology shows potential for the treatment of syringoma in a feasibility studyDermWireTV: Cosentyx for Kids; Anifrolumab for SLE, Tremfya in PsA at EULAR
https://practicaldermatology.com/topics/psoriasis/dermwiretv-cosentyx-for-kids-anifrolumab-for-sle-tremfya-in-psa-at-eular/19948/FDA has approved Cosentyx (secukinumab) from Novartis for patients as young as six years old. The 2nd Annual San Diego Dermatology Symposium kicks off as a live Virtual Experience next Friday. A post-hoc analysis of pooled data from the TULIP Phase 3 clinical trials shows that anifrolumab improvesPatients types that may be a great fit for ILUMYA™
https://practicaldermatology.com/topics/psoriasis/patients-types-that-may-be-a-great-fit-for-ilumya/19859/See how ILUMYA™ is a treatment option for a diverse range of patients with moderate-to-severe plaque psoriasis, including bio-naive and bio-experienced patients, and those aged 65 years or older.Troubleshooting teledermatology
https://practicaldermatology.com/topics/practice-management/troubleshooting-teledermatology/19854/Doctors and patients alike praise the ability of technology to enable virtual care, but this rapid transition has not been entirely trouble-free. In this video from Ekwa Marketing, we look at some of the most common problems, and how you might be able to avoid or solve them.DERM2020 NP/PA CME Conference Thank You from DEF President Joe Gorelick, MSN, FNP-C
https://practicaldermatology.com/conferences/dermatology-education-foundation-derm-2020/derm2020-nppa-cme-conference-thank-you/19837/Joe Gorelick thanks the participants for DERM2020 Session 1 – all live webinars from August 6 – 11, 2020!Scientifically Speaking: Botulinum Toxin Formulation and Testing
https://practicaldermatology.com/series/scientifically-speaking/scientifically-speaking-botulinum-toxin-formulation-and-testing/19832/Ever wonder about the differences in formulation and manufacture of botulinum neurotoxins? Curious about the trials that support approval? In this edition of Scientifically Speaking, Joel L. Cohen, MD gets the answers to these questions and more from Conor Gallagher, PhD, Head of Medical Affairs, ReNovel Treatments for Acne
https://practicaldermatology.com/topics/acne-rosacea/novel-treatments-for-acne/19761/Joshua Zeichner, MD discusses three new treatments now available in the acne treatment armamentarium. For patients with severe acne, a new low-dose isotretinoin in a micronized formulation allows for better absorption, even without food. Dr. Zeichner also discusses the benefits of a new topical reti